Brief: Geron Corp Expects To Submit A Marketing Authorization Application In EU In Second Half Of 2023
20/06/2023 14:18
June 20 (Reuters) - Geron Corp GERN.O :
* GERON ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION TO FDA
FOR
FIRST-IN-CLASS TELOMERASE INHIBITOR IMETELSTAT
* GERON CORP: EXPECTS TO SUBMIT A MARKETING AUTHORIZATION
APPLICATION (MAA) IN EU IN SECOND HALF OF 2023
Source text for Eikon: ID:nBw3LCSCMa
Further company coverage: GERN.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Geron
See all newsBrief: Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Geron Corporation reports results for the quarter ended June 30 - Earnings Summary
Geron's Q2 revenue rises on RYTELO growth
Brief: Geron Q2 EPS USD -0.02
Brief: Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)